33 studies found for:    Migraine AND 2 hours post-dose
Show Display Options
Rank Status Study
1 Completed
Has Results
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
Condition: Migraine
Interventions: Drug: MK0974 50 mg;   Drug: MK0974 150 mg;   Drug: MK0974 300 mg;   Drug: Comparator: Placebo
2 Completed
Has Results
Migraine Study in Adolescent Patients
Condition: Migraine Disorders
Interventions: Drug: Sumatriptan and Naproxen Sodium;   Drug: Placebo
3 Completed
Has Results
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)(COMPLETED)
Condition: Migraine
Interventions: Drug: Comparator: rizatriptan benzoate;   Drug: Comparator: Placebo
4 Completed
Has Results
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
Condition: Migraine, Acute
Interventions: Drug: rizatriptan;   Drug: placebo
5 Completed A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
Condition: Migraine
Interventions: Drug: MK-1602;   Drug: Placebo;   Drug: Rescue medication
6 Completed A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
Condition: Migraine
Interventions: Drug: MK-1602;   Drug: Placebo;   Drug: Rescue medication
7 Completed
Has Results
Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea
Condition: Migraine
Interventions: Drug: Comparator: Rizatriptan;   Drug: Comparator: Placebo
8 Terminated Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches
Condition: Migraine Headache
Intervention: Drug: NPS 1776
9 Completed MK0974 Pivotal Study 1 - WW (With Active Comparator)(0974-011)(COMPLETED)
Condition: Migraine
Interventions: Drug: MK0974 / Duration of Treatment: 1 Day;   Drug: Comparator: zolmitriptan / Duration of Treatment: 1 Day;   Drug: Comparator: placebo (unspecified) / Duration of Treatment: 1 Day
10 Completed
Has Results
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
Condition: Migraine, Without Aura
Interventions: Drug: sumatriptan succinate / naproxen sodium;   Drug: Placebo
11 Completed
Has Results
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
Conditions: Migraine With or Without Aura;   Migraine Disorders;   Migraine
Interventions: Drug: Placebo;   Drug: Combination Product (sumatriptan succinate/naproxen sodium)
12 Completed
Has Results
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)
Conditions: Migraine With or Without Aura;   Migraine Disorders;   Migraine, Acute
Interventions: Drug: Combination Product (sumatriptan succinate / naproxen sodium);   Drug: Placebo
13 Completed Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Conditions: Migraine Without Aura;   Migraine With Aura
Interventions: Drug: Placebo;   Drug: Eletriptan HBr 40 mg;   Drug: Eletriptan HBr 80 mg
14 Completed
Has Results
Two Rizatriptan Prescribing Portions for Treatment of Migraine
Condition: Migraine
Intervention: Drug: rizatriptan
15 Completed
Has Results
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Condition: Acute Migraine With or Without Aura in Adolescents
Intervention: Drug: rizatriptan benzoate
16 Terminated Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
Condition: Migraine
Interventions: Drug: BGC20-1531;   Drug: Lactose
17 Completed A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
Conditions: Migraine;   Head Pain;   Headache
Intervention: Drug: tramadol HCl/acetaminophen
18 Completed Study to Test an Approved Product in the Early Treatment of Migraine
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day
19 Completed Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-autonomic Symptoms.
Condition: Migraine
Intervention: Drug: rizatriptan or placebo
20 Completed Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)(COMPLETED)
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day

Previous Page Studies Shown (1-20) Next Page (21-33) Show next page of results
Indicates status has not been verified in more than two years